Delcath Systems, Inc. Files Material Definitive Agreement
Ticker: DCTH · Form: 8-K · Filed: Apr 26, 2024 · CIK: 872912
Sentiment: neutral
Topics: material-agreement
TL;DR
DELCATH signed a big deal, details TBD.
AI Summary
On April 22, 2024, Delcath Systems, Inc. entered into a Material Definitive Agreement. The filing does not specify the nature of the agreement or any associated dollar amounts or specific parties involved.
Why It Matters
This filing indicates a significant new contract or partnership for Delcath Systems, Inc., which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the material definitive agreement.
Key Players & Entities
- DELCATH SYSTEMS, INC. (company) — Registrant
- April 22, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Delcath Systems, Inc. on April 22, 2024?
The filing does not specify the nature of the Material Definitive Agreement.
Are there any specific parties named in the Material Definitive Agreement?
The filing does not name any specific parties to the agreement.
Were any dollar amounts disclosed in relation to this Material Definitive Agreement?
No dollar amounts are disclosed in this filing concerning the agreement.
What is the Commission File Number for Delcath Systems, Inc.?
The Commission File Number for Delcath Systems, Inc. is 001-16133.
What is the principal executive office address for Delcath Systems, Inc.?
The address of the principal executive offices is 566 Queensbury Avenue, Queensbury, New York 12804.
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 14.9 · Accepted 2024-04-26 08:25:30
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value DCTH The Nasdaq Capital M
Filing Documents
- d711286d8k.htm (8-K) — 22KB
- 0001193125-24-115922.txt ( ) — 137KB
- dcth-20240422.xsd (EX-101.SCH) — 3KB
- dcth-20240422_lab.xml (EX-101.LAB) — 17KB
- dcth-20240422_pre.xml (EX-101.PRE) — 11KB
- d711286d8k_htm.xml (XML) — 3KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 DELCATH SYSTEMS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-16133 06-1245881 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 566 Queensbury Avenue Queensbury , New York 12804 (Address of principal executive offices) (212) 489-2100 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value DCTH The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item1.01 Entry into a Material Definitive Agreement. On April 22, 2024, Delcath Systems, Inc. ("Delcath") entered into a Fifth Amendment, effective May 1, 2024 (the "Amendment"), to the License, Supply and Contract Manufacturing Agreement with Synerx Pharma, LLC and Mylan Teoranta, dated October 13, 2010 (as subsequently amended, the "Agreement"), for Delcath's supply of melphalan hydrochloride (the "Product"). The Amendment (i) extends the term of the Agreement to December 31, 2028; (ii) requires Delcath to place purchase orders for the Product at least 210 days before the delivery date; (iii) modifies the price per vial for the Product; and (iv) provides for certain annual price increases for the Product equivalent to the percent increase of the published producer price index for pharmaceutical preparation and manufacturing measured per calendar year. The foregoing description of the Amendment is not complete and is qualified in its entirety by the full text of the Amendment, a copy of which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. DELCATH SYSTEMS, INC. Date: April 26, 2024 By: /s/ Gerard Michel Name: Gerard Michel Title: Chief Executive Officer